Peptides DB
Research-centric peptide and protocol reference hub
Study 15 of 15IGF-1 DES (Des(1-3) IGF-1) literatureDEN open · Observational2026

Risk Factors for Peritonitis Associated With Endoscopic Ultrasound-guided Hepaticogastrostomy.

A bile duct diameter of ≤3 mm during EUS-HGS is a significant risk factor for peritonitis, suggesting careful consideration during the procedure.

Read at DEN openAdd to compare

Where it sits

this study against the rest of the igf-1 des (des(1-3) igf-1) corpus
1
Preclinical
10
Observational · this one
0
Open-label
3
Randomised
1
Reviews

Summary and findings

This study retrospectively evaluated 188 patients who underwent endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) to identify risk factors for peritonitis. The analysis found that a bile duct diameter of ≤3 mm significantly increased the risk of peritonitis. The study focused on patients with malignant biliary obstruction, primarily due to pancreatic cancer.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Bile duct diameter ≤3 mm had an odds ratio of 4.0 for peritonitis, p=0.039.n=1882026

Abstract

The authors’ words, as DEN open supplied them

<h4>Background and objectives</h4>Endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) is an alternative therapeutic option for unsuccessful endoscopic retrograde cholangiopancreatography in patients with malignant biliary obstruction. Procedure-related adverse events (AEs), such as bile leakage and peritonitis, can lead to prolonged hospitalization and delay the initiation of chemotherapy for underlying malignancies. This study aimed to identify factors associated with the development of peritonitis following EUS-HGS.<h4>Methods</h4>Consecutive patients who underwent initial EUS-HGS between July 2016 and November 2022 were retrospectively evaluated. We assessed the preprocedural characteristics (cholangitis and duodenal invasion) and intraprocedural technical factors (small bile duct diameter, short hepatic parenchymal distance at puncture, antegrade stenting, and the use of a plastic stent for HGS). Multivariate logistic regression analysis was conducted to evaluate the factors associated with peritonitis after EUS-HGS.<h4>Results</h4>A total of 188 patients were included. The cause of biliary obstruction was malignancy in 96% of the cases, with the majority being pancreatic cancer. The rate of early AEs was 15% and included peritonitis (7%), pancreatitis (3%), cholangitis (3%), cholecystitis (1%), and bleeding (1%). Multivariable logistic regression analysis revealed that the diameter of a punctured bile duct ≤3 mm (odds ratio, 4.0; 95% confidence interval, 1.1-15; <i>p</i> = 0.039) independently increased the risk of peritonitis after EUS-HGS.<h4>Conclusions</h4>A punctured bile duct diameter of ≤3 mm was identified as a significant independent risk factor for the development of peritonitis after EUS-HGS. <b>Trial Registration</b>: N/A.

Background

The study addresses the clinical question of identifying risk factors for peritonitis following endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS), a procedure used when endoscopic retrograde cholangiopancreatography fails in patients with malignant biliary obstruction. Peritonitis is a significant adverse event that can delay necessary chemotherapy. Understanding these risk factors is crucial for improving patient outcomes and procedural safety.

Methods

This retrospective study included 188 consecutive patients who underwent initial EUS-HGS between July 2016 and November 2022. The study evaluated preprocedural characteristics such as cholangitis and duodenal invasion, as well as intraprocedural factors like bile duct diameter and stenting techniques. Multivariate logistic regression was used to identify factors associated with peritonitis.

Results

Among the 188 patients, 96% had biliary obstruction due to malignancy, predominantly pancreatic cancer. The overall rate of early adverse events was 15%, with peritonitis occurring in 7% of cases. The multivariable logistic regression identified a bile duct diameter of ≤3 mm as a significant independent risk factor for peritonitis, with an odds ratio of 4.0 and a p-value of 0.039.

Interpretation

The study highlights a specific procedural risk factor for peritonitis, a serious complication of EUS-HGS. The finding that a bile duct diameter of ≤3 mm significantly increases the risk of peritonitis is statistically significant but may have limited clinical applicability due to the study's retrospective nature and potential confounding factors. These results should be interpreted with caution and validated in prospective studies.

Key findings

  • 188 patients underwent EUS-HGS.
  • 96% of biliary obstructions were due to malignancy.
  • The early adverse event rate was 15%.
  • Peritonitis occurred in 7% of cases.
  • Bile duct diameter ≤3 mm had an odds ratio of 4.0 for peritonitis, p=0.039.

Limitations

  • Retrospective study design
  • Single-center data
  • Potential selection bias
  • Specific to EUS-HGS procedure
  • No prospective validation

Elsewhere in the IGF-1 DES (Des(1-3) IGF-1) corpus

ADiscontinuation of statins for primary prevention of atherosclerotic cardiovascular disease in adults aged 75 years or older (SAGA/SITE): a multicentre, open-label, pragmatic, non-inferiority randomised trial.The lancet. Healthy longevity · 2026 · n=1160 · The absolute difference in all-cause mortality between groups was -0.68% (95% CI -3.95 to 2.60).HumanAEfficacy and safety of filgotinib in patients with active radiographic and nonradiographic axial spondyloarthritis: results from OLINGUITO, a phase 3 trial consisting of 2 randomised, placebo-controlled, double-blind, parallel-group studies.Annals of the rheumatic diseases · 2026 · n=495 · 39.5% ASAS40 response in r-axSpA filgotinib group vs 20.9% PBO, P=0.001, n=258.HumanBClinical Outcomes After Failed Endoscopic Detorsion for Sigmoid Volvulus: A Single-Center Retrospective Cohort Study.DEN open · 2026 · Successful detorsion achieved in 21 of 43 patients (48.8%).HumanBRisk Stratification for Rebleeding in Obscure Gastrointestinal Bleeding After Comprehensive Gastrointestinal Evaluation.DEN open · 2026 · Rebleeding rates were 5.6%, 17.5%, 27.3%, and 100% for scores 0, 1, 2, and 3, respectively.HumanBClinical Utility and Safety of a Novel Ultraslim Catheter-Type Peroral Cholangioscope/Pancreatoscope: A Single-Center Case Series.DEN open · 2026 · Clinical success achieved in 11/12 cases (91.7%)HumanDState of the global tuberculosis epidemic: burden, progress towards WHO End TB Strategy targets and systemic challenges.The Lancet. Microbe · 2026 · 10.7 million people developed tuberculosis in 2024.